Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease.

Liu H, He J, Koh SP, Zhong Y, Liu Z, Wang Z, Zhang Y, Li Z, Tam BT, Lin P, Xiao M, Young KH, Amini B, Starbuck MW, Lee HC, Navone NM, Davis RE, Tong Q, Bergsagel PL, Hou J, Yi Q, Orlowski RZ, Gagel RF, Yang J.

Sci Transl Med. 2019 May 29;11(494). pii: eaau9087. doi: 10.1126/scitranslmed.aau9087.

PMID:
31142679
2.

Intravital microscopy of osteolytic progression and therapy response of cancer lesions in the bone.

Dondossola E, Alexander S, Holzapfel BM, Filippini S, Starbuck MW, Hoffman RM, Navone N, De-Juan-Pardo EM, Logothetis CJ, Hutmacher DW, Friedl P.

Sci Transl Med. 2018 Aug 1;10(452). pii: eaao5726. doi: 10.1126/scitranslmed.aao5726.

PMID:
30068572
3.

Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma.

Liu H, Liu Z, Du J, He J, Lin P, Amini B, Starbuck MW, Novane N, Shah JJ, Davis RE, Hou J, Gagel RF, Yang J.

Sci Transl Med. 2016 Aug 24;8(353):353ra113. doi: 10.1126/scitranslmed.aad8949.

4.

Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.

Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Li Ning Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM.

Sci Transl Med. 2014 Sep 3;6(252):252ra122. doi: 10.1126/scitranslmed.3009332. Erratum in: Sci Transl Med. 2015 May 13;7(287):287er3. Tapia, Elsa M Li-Ning [corrected to Li Ning Tapia, Elsa M].

5.

Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma.

Yang J, He J, Wang J, Cao Y, Ling J, Qian J, Lu Y, Li H, Zheng Y, Lan Y, Hong S, Matthews J, Starbuck MW, Navone NM, Orlowski RZ, Lin P, Kwak LW, Yi Q.

Leukemia. 2012 Sep;26(9):2114-23. doi: 10.1038/leu.2012.71. Epub 2012 Mar 19. Erratum in: Leukemia. 2015 Feb;29(2):515.

6.

Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells.

Wan X, Liu J, Lu JF, Tzelepi V, Yang J, Starbuck MW, Diao L, Wang J, Efstathiou E, Vazquez ES, Troncoso P, Maity SN, Navone NM.

Clin Cancer Res. 2012 Feb 1;18(3):726-36. doi: 10.1158/1078-0432.CCR-11-2521.

7.

Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.

Wan X, Li ZG, Yingling JM, Yang J, Starbuck MW, Ravoori MK, Kundra V, Vazquez E, Navone NM.

Bone. 2012 Mar;50(3):695-703. doi: 10.1016/j.bone.2011.11.022. Epub 2011 Dec 7.

8.

Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.

Mohamedali KA, Li ZG, Starbuck MW, Wan X, Yang J, Kim S, Zhang W, Rosenblum MG, Navone NM.

Clin Cancer Res. 2011 Apr 15;17(8):2328-38. doi: 10.1158/1078-0432.CCR-10-2943. Epub 2011 Feb 22.

9.

Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation.

Araujo JC, Poblenz A, Corn P, Parikh NU, Starbuck MW, Thompson JT, Lee F, Logothetis CJ, Darnay BG.

Cancer Biol Ther. 2009 Nov;8(22):2153-9. Epub 2009 Nov 8.

10.

Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms.

Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM.

J Clin Invest. 2008 Aug;118(8):2697-710. doi: 10.1172/JCI33093.

11.

Bone morphogenetic protein type IA receptor signaling regulates postnatal osteoblast function and bone remodeling.

Mishina Y, Starbuck MW, Gentile MA, Fukuda T, Kasparcova V, Seedor JG, Hanks MC, Amling M, Pinero GJ, Harada S, Behringer RR.

J Biol Chem. 2004 Jun 25;279(26):27560-6. Epub 2004 Apr 16.

Supplemental Content

Loading ...
Support Center